ARUP launches Clarispect myeloma MRD assay
September 2026—ARUP Laboratories has launched ARUP Clarispect Multiple Myeloma MRD by Spectral Flow Cytometry.
Webinars and Sponsored Roundtables — Register Now
Tuesday, October 20, 2026, 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Roche.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.
Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Subspecialties
Interactive Product Guides
Marketplace
Atellica testosterone assay gets CDC HoSt-TT certification
September 2026—Siemens Healthineers’ Atellica IM Testosterone II assay has achieved certification through the Centers for Disease Control and Prevention hormone standardization program for total testosterone, confirming that the Atellica IM TSTII immunoassay’s test results are equivalent to high-performance liquid chromatography coupled with tandem mass spectrometry.
BD Bactec FXI culture system gets FDA clearance
September 2026—Waters Corp. announced that the BD Bactec FXI culture system has received FDA 510(k) clearance.
Streck launches MDx-Chex for respiratory testing
September 2026—Streck has released its MDx-Chex for RP molecular quality control designed for high-plex respiratory testing panels.
New York approves Haystack MRD test
September 2026—The New York State Clinical Laboratory Evaluation Program has approved Quest Diagnostics’ Haystack MRD test.
Leica Biosystems expands collaboration with AstraZeneca, Daiichi Sankyo
September 2026—Leica Biosystems has expanded its collaboration with AstraZeneca and Daiichi Sankyo to develop an immunohistochemistry assay and image analysis algorithm for the TROP2 normalized membrane ratio biomarker in non-small cell lung cancer, for use as a research tool only.
Quest extends oncology test access through OncoEMR MPI
September 2026—Quest Diagnostics is integrating its Haystack MRD ctDNA test and comprehensive genomic profiling services for solid tumor cancers within OncoEMR, an EHR from Flatiron Health, via a pilot program with American Oncology Network and other community oncology providers.
FDA clears PrecivityAD2 test
September 2026—The FDA has cleared C2N Diagnostics’ PrecivityAD2 test, indicated for use in adults aged 40 years and older who present with signs or symptoms of cognitive impairment undergoing evaluation for Alzheimer’s disease or other forms of cognitive decline.
NEB releases Monarch Mag cfRNA extraction kit
September 2026—New England Biolabs released the Monarch Mag Cell-free RNA Extraction kit, which enables isolation of low-abundance cfRNA and exome-associated RNA from biofluids including plasma, serum, urine, and cerebrospinal fluid.
Seegene analysis shows limits of single-pathogen respiratory testing
September 2026—Seegene has released findings from an analysis of approximately 260,000 pediatric respiratory PCR test results collected over 42 months from children aged zero to five years.